RT Journal Article
T1 Pre-diagnostic metabolite concentrations and prostate cancer risk in 1077 cases and 1077 matched controls in the European Prospective Investigation into Cancer and Nutrition.
A1 Schmidt, Julie A
A1 Fensom, Georgina K
A1 Rinaldi, Sabina
A1 Scalbert, Augustin
A1 Appleby, Paul N
A1 Achaintre, David
A1 Gicquiau, Audrey
A1 Gunter, Marc J
A1 Ferrari, Pietro
A1 Kaaks, Rudolf
A1 Kühn, Tilman
A1 Floegel, Anna
A1 Boeing, Heiner
A1 Trichopoulou, Antonia
A1 Lagiou, Pagona
A1 Anifantis, Eleutherios
A1 Agnoli, Claudia
A1 Palli, Domenico
A1 Trevisan, Morena
A1 Tumino, Rosario
A1 Bueno-de-Mesquita, H Bas
A1 Agudo, Antonio
A1 Larrañaga, Nerea
A1 Redondo-Sánchez, Daniel
A1 Barricarte, Aurelio
A1 Huerta, José Maria
A1 Quirós, J Ramón
A1 Wareham, Nick
A1 Khaw, Kay-Tee
A1 Perez-Cornago, Aurora
A1 Johansson, Mattias
A1 Cross, Amanda J
A1 Tsilidis, Konstantinos K
A1 Riboli, Elio
A1 Key, Timothy J
A1 Travis, Ruth C
K1 Acylcarnitines
K1 Amino acids
K1 Biogenic amines
K1 European Prospective Investigation into Cancer and Nutrition (EPIC)
K1 Glycerophospholipids
K1 Hexose
K1 Mass spectrometry
K1 Metabolomics
K1 Prospective study
K1 Prostate cancer risk
K1 Sphingolipids
AB Little is known about how pre-diagnostic metabolites in blood relate to risk of prostate cancer. We aimed to investigate the prospective association between plasma metabolite concentrations and risk of prostate cancer overall, and by time to diagnosis and tumour characteristics, and risk of death from prostate cancer. In a case-control study nested in the European Prospective Investigation into Cancer and Nutrition, pre-diagnostic plasma concentrations of 122 metabolites (including acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexose and sphingolipids) were measured using targeted mass spectrometry (AbsoluteIDQ p180 Kit) and compared between 1077 prostate cancer cases and 1077 matched controls. Risk of prostate cancer associated with metabolite concentrations was estimated by multi-variable conditional logistic regression, and multiple testing was accounted for by using a false discovery rate controlling procedure. Seven metabolite concentrations, i.e. acylcarnitine C18:1, amino acids citrulline and trans-4-hydroxyproline, glycerophospholipids PC aa C28:1, PC ae C30:0 and PC ae C30:2, and sphingolipid SM (OH) C14:1, were associated with prostate cancer (p  Several metabolites, i.e. C18:1, citrulline, trans-4-hydroxyproline, three glycerophospholipids and SM (OH) C14:1, might be related to prostate cancer. Analyses by time to diagnosis indicated that citrulline may be a marker of subclinical prostate cancer, while other metabolites might be related to aetiology. Several glycerophospholipids were inversely related to advanced stage disease. More prospective data are needed to confirm these associations.
YR 2017
FD 2017-07-05
LK http://hdl.handle.net/10668/11372
UL http://hdl.handle.net/10668/11372
LA en
DS RISalud
RD Apr 8, 2025